| Product | Specifications | Indication | Research | Preclinical | Clinical Phase I |
Clinical Phase II |
Clinical Phase III |
|---|---|---|---|---|---|---|---|
| RF-GS03 | Stem Cell Therapy | Autoimmune Inner Ear Disease (AIED) | ● | ||||
| RF-GS04 | siRNA Gene Therapy | Autoimmune Sjogren’s Syndrome | ● | ||||
| RF-A02 | Antibody Drug | Rheumatis Arthritis | ● | ||||
| RF-A05 | Antibody Drug | Lung Cancer | ● | ||||
| RF-G01 | Gene Therapy | Neuroblastoma Chemotherapy | ● |
- Treatment Method
- Adipose-derived Stem Cell (ADSC) Therapy
- Mechanisms
- ADSC therapy: While inducing regulatory-T cells,
we seek to maintain cytokine balance and homeostasis in order
to increase therapeutic effect.
- Federal Grant
- Chungcheongbuk-do Advanced Medical Care Technologies Value Creation Grant selection (Funding: $200,000 for 1 year)
- Collaborators
- Osong Medical Innovation Foundation’s New Drug Development Center and Laboratory Animal Center
Autoimmune Inner Ear Disease (AIED) is a inflammatory condition caused by antibodies or immune cells that attack the inner ear. This syndrome is marked by progressive hearing loss and/or dizziness usually accompanied by tinnitus (ringing, hissing, or roaring sounds in the ear). In some cases, AIED resembles Meniere’s disease due to high concentrations of antibody formation in the blood. About 1% of patients with ear problems are known to have AIED.
- Cytokine and/or immune
- responses to injury or
trauma to the inner ear,
which can cause provoke - autoimmune reactions
- Antibody and/or rogue-T cell
- responses to potentially
harmful substances, viruses
or bacteria sharing common antigens with the inner ear
- Immune cell responses to
inner ear antigens released post-surgery or infection,
which can cause the body
to wrongfully recognize
the antigens as foreign
- Genetically controlled aspects
of the immune system may cause autoimmune responses
* ROPHIBIO’s current project has been funded by the Chungcheongbuk-do’s Advanced Medical Care Technologies Value Creation grant and supported with infrastructure provided by Osong KBIO’s New Drug Development Center and Laboratory Animal Center.
- Treatment Method
- Adeno-Associate Virus (AAV-2) siRNA Gene Therapy
- Mechanisms
- A. Synthetic gene promoter technology
B. Personalized medicine based on patient’s profile - Mechanisms
- A. Synthetic gene promoter technology
(synthetic gene promoter technology)
B. Personalized medicine based on patient’s profile
(personalized medicine)
- Benefits
- We seek to utilize siRNA gene therapy to suppress the overexpression of BMP-6 while increasing expression of the water channel protein, Aquaporin-5, in salivary gland cells. The natural secretion of saliva would ease symptoms related to tissue damage.
- Federal Grant
- Ministry of Trade, Industry and Energy (MOTIE) International Joint Technology Development Grant application in progress (Funding: $500,000 per year; $1,500,000 for 3 years)
- Collaborators
- A. Advance Medigene (Zhenan Lai, Ph.D.)
B. National Institute of Health (National Institute of Dental and Craniofacial Research)
C. Moffitt Cancer Center (Jong Park, Ph.D.)
D. University of Florida (Seunghee Cha, Ph.D.)
E. Osong KBIO’s New Drug Development Center and Laboratory Animal Center
- • Neuropathy
• Dry nose and sinusitis
• Vasculitis
• Peripheral neuropathy
• Raynaud’s disease
• Joint and muscle pain
• Bronchitis
• Gastroparesis
- • Concentration
and memory loss
• Dry skin
• Dry eyes
• Dry mouth
• Periodontal disease
• Arthritis
• Vaginal dryness
- • Anxiety
• Hot flashes
• Insomnia
• Cardiovascular disease
• Perspiration
• Osteoporosis
• Dysuria
Sjogren’s syndrome is a chronic inflammatory condition caused by white blood cells that attack the saliva and tear glands. This syndrome is marked by dry mouth and dry eyes and can cause significant deterioration to the patient’s quality of life. The cause of Sjogren’s syndrome is currently unknown and there are no known cures for the disease.
However, it is known that 60% of patients with Sjogren’s syndrome show an overexpression of BMP-6. ROPHIBIO’s strategy is to regulate BMP-6 to normal levels by injecting AAV mounted with BMP-6 RNAi into the patient’s salivary glands. Furthermore, ROPHIBIO seeks to utilize it’s targeting promoter technologies as well as the patient’s genetic profiling in order to maximize safety and to maximize therapeutic effects.
- Treatment Method
- Recombinant Antibody Drug Therapy
- Mechanisms
- We seek to normalize the cytokine imbalances that cause
autoimmune disease while suppressing signal transducer
and activator of transcription 3 (STAT3), whichis the cause
for overexpression of TNF-a and IL-6. - Specifics
- ROPHIBIO is currently developing a cell-penetrating bi-specific
antibody to suppress STAT3.
This antibody will consider the mechanisms for the activation of
STAT3 via phosphorylation of tyrosine residue in order to
selectively control the expression of STAT3.
- Benefits
- By using cell-penetrating bi-specific antibodies to selectively suppress STAT3, we are able to reduce side effects and toxicity while increasing controlled therapeutic effects.
- Potential Effects
- Our cell-penetrating bi-specific antibody will allow us to develop further therapies targeting various transcription factors.
This new development will allow us to treat not only rheumatoid arthritis, but also hundreds of other known autoimmune diseases. - Collaborators
- A. Chungbuk National University, Department of Pharmaceuticals
B. Cheongju University, Biomedical Department
C. Osong KBIO’s New Drug Development Center
